Safety, tolerance, and enhanced efficacy of a bioavailable formulation of curcumin with fenugreek dietary fiber on occupational stress a randomized, double-blind, placebo-controlled pilot study

Journal of Clinical Psychopharmacology

Volumn 36, Issue 3, 2016, Pages 236-243

  Sudheeran, Subash Pandaran ^a   Jacob, Della ^a   Mulakal, Johannah Natinga ^b   Nair, Gopakumar Gopinathan ^b   Maliakel, Abhilash ^b   Maliakel, Balu ^b   Kuttan, Ramadasan ^c   Kumar, Krishna ^b  

^a SMO Connect Clinical Research Services Pvt Ltd   (India)

^b R and D Laboratory   (India)

^c AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Anxiety; Bioavailability; Curcuminoids; Occupational stress; Oxidative stress; Safety

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; CATALASE; CURCUMAGALACTOMANNOSIDE; CURCUMIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; NATURAL PRODUCT; PLACEBO; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; FENUGREEK SEED MEAL; PLANT EXTRACT;

ADULT; ANTIOXIDANT ACTIVITY; ANXIETY; ARTICLE; BECK ANXIETY INVENTORY; BEDTIME DOSAGE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DECREASED APPETITE; DIETARY FIBER; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FENUGREEK; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; JOB STRESS; LIPID PEROXIDATION; MALE; MORNING DOSAGE; NORMAL HUMAN; PHARMACOKINETIC PARAMETERS; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SHORT FORM 36; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; BIOAVAILABILITY; BLOOD; DRUG EFFECTS; DRUG THERAPY; MENTAL STRESS; METABOLISM; OCCUPATIONAL EXPOSURE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PSYCHOLOGY; TREATMENT OUTCOME; TRIGONELLA;

ADMINISTRATION, ORAL; ADULT; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CURCUMIN; DIETARY FIBER; DOUBLE-BLIND METHOD; DRUG COMPOUNDING; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; OCCUPATIONAL EXPOSURE; PILOT PROJECTS; PLANT EXTRACTS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME; TRIGONELLA;

EID: 84962128074     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000508     Document Type: Article

References (46)

1. Marotta F, Naito Y, Padrini F, et al. Redox balance signalling in occupational stress: modification by nutraceutical intervention. J Biol Regul Homeost Agents. 2011;25:221-229.
2. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev. 2009;2:63-67.
3. Deshpande RC. A healthy way to handle work place stress through yoga, meditation and soothing humor. Int J Environ Sci. 2012;2:2143-2154.
4. Lobo V, Patil A, Phatak A, et al. Free radicals, antioxidants and functional foods: Impact on human health. Phcog Rev. 2010;4:118-126.
5. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J. 2013;15:195-218.
6. Lin JK. Molecular targets of curcumin. Adv Exp Med Biol. 2007;595: 227-243.
7. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Comp Altern Med. 2006;17:6-10.
8. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74:664-669.
9. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28:1765-1773.
10. Pal A, Sung B, Bhanu Prasad BA, et al. Curcuminglucuronides: Assessing the proliferative activity against human cell lines. Bioorg Med Chem. 2014; 22:435-439.
11. Ma Q-L, Zuo X, Yang F, et al. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem. 2013;288:4056-4065.
12. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280:5892-5901.
13. Heger M, Van GRF, Broekgaarden M, et al. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2013;66:222-307.
14. Jager R, Lowery RP, Calvanese AV, et al. Comparative absorption of curcumin formulations. Nutrition J. 2014;13:11.
15. Schiborr C, Kocher A, Behnam D, et al. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014;58:516-527.
16. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34: 660-665.
17. Krishnakumar IM, Maliakel A, Gopakumar G, et al. Improved blood- brain-barrier permeability and tissue distribution following the oral administration of a food-grade formulation of curcumin with fenugreek fiber. J Funct Foods. 2015;14:215-225.
18. Krishnakumar IM, Ravi A, Kumar D, et al. An enhanced bioavailable formulation of curcumin using fenugreek-derived soluble dietary fiber. J Funct Foods. 2012;4:348-357.
19. Bergman J, Miodownik C, Bersudsky Y, et al. Curcumin as an add-on to antidepressive treatment: A randomized double-blind, placebo-controlled pilot clinical study. Clin Neuropharmacol. 2013;36:73-77.
20. Chimakurthy J, Talasila M. Effects of curcumin on pentylenetetrazole-induced anxiety like behavior and associated changes in cognition and monoamine levels. Psychol Neurosci. 2010;3:238-244.
21. Brondino N, Re S, Boldrini A, et al. Curcumin as a therapeutic agent in dementia: A mini systematic review of human studies. Scientific World Journal. 2014; Article ID 174282, 6 pages. Retrieved from http://dx.doi.org/10.1155/2014/174282.
22. Wade JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30: 473-483.
23. Cohen S, Kamarck T, Mermelstein RA. A global measure of perceived stress. J Health Soc Behav. 1983;24:385-396.
24. Beck AT, Epstein NG, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol. 1988;56: 893-897.
25. McCord JM, Fridovich I. The utility of superoxide dismutase in studying free radical reactions I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. J Biol Chem. 1969;244:6056-6063.
26. Aebi H. Catalase, in Methods in Enzymatic analysis, ed. Bergmeyer HU, Academic press Inc, New York, 1974;2:673.
27. Moron MS, De Pierre JN, Mannervik V. Levels of glutathione, glutathione reductase, and glutathione -S- Transferase in rat lung and liver. Biochem Biophys Acta. 1979;582:67-68.
28. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Lab Clin Med. 1967;70:158-169.
29. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
30. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos Biol. 1999;27: 486-494.
31. Pawar YB, Bhushan M, Saurabh A, et al. Bioavailability of a lipidic formulation of curcumin in healthy human volunteers. Pharmaceutics. 2012;4:517-530.
32. Liju VB, Jeena K, Kumar D, et al. Enhanced bioavailability and safety of curcumagalactomannosides as a dietary ingredient. Food Funct. 2015;6: 275-285.
33. Administration USFDA. Substances Generally Regarded as Safe. Essential oils, oleoresins (solvent free), and natural extractives. 2014; Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182.
34. Srivastava M, Kapoor V. Seed galactomannans: An overview. Chem Biodivers. 2005;2:295-317.
35. Corns CM. Herbal remedies and clinical biochemistry. Ann Clin Biochem. 2003;40:489-507.
36. O'Donnell J, Ahuja GD. Drug injury: Liability, Analysis, and Prevention. 2nd ed. Tucson, AZ: US Lawyers & Judges Publishing Company; 2005.
37. Ramaiah SK. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem Toxicol. 2007;45:1551-1557.
38. Kaplan MM, Chang NC, Chan NM. Biochemical basis for serum enzyme abnormalities in alcoholic liver disease (in Early identification of alcohol abuse). Research Monograph. 1995;17:180-186.
39. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14: 4491-4499.
40. Gota VS, Maru GB, Soni TG, et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in Osteosarcoma patients and healthy volunteers. J Agri Food Chem. 2010;58:2095-2099.
41. Urso ML, Clarkson PM. Oxidative stress, exercise, and antioxidant supplementation. Toxicology. 2003;189:41-54.
42. Sahebkar A, Serban MC, Ursoniu S, et al. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. J Funct Foods. 2015;18:898-909.
43. Mates J. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology. 2000;153:83-104.
44. Filomeni G, Rotilio G, Ciriolo MR. Cell signaling and the glutathione redox system. Biochem Pharmacol. 2002;64:1057-1064.
45. Aruoma OI. Free radicals, oxidative stress, and antioxidants in human health and disease. J Am Oil Chem Soc. 1998;75:199-212.
46. SuK P. Inflammation in psychopathology of depression: clinical, biological, and therapeutic implications. Bio Med. 2012;2:68-74.